Search

Displaying results 781 - 790 of 10000 in total
  1. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis. … Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent.

  2. Drug

    Benzylpenicillin

    go.drugbank.com/drugs/DB01053
    ApprovedInvestigationalVet approved

    The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix … Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.

    Mixtures: BENZAPEN 6.3.3 IM ENJ TOZ ICEREN FLAKON, 1 ADET, BENZAPEN 6.3.3 IM ENJ TOZ ICEREN FLAKON, 1 ADETProducts: Novo-pen G 500
  3. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    therapy developed by Mayne Pharma in 1992. … An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.

    Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200
  4. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019. … [L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872]

  5. Drug

    VIS-410

    go.drugbank.com/drugs/DB19067
    Investigational

    VIS-410 is under investigation in clinical trial NCT03040141 (Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A).

  6. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials … [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being

  7. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as … Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth

  8. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    in high risk adolescents and adults. … [L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]

    Mixtures: EMTRICITABINA E TENOFOVIR DISOPROXIL EG, EMTRICITABINA E TENOFOVIR DISOPROXIL EGCategories: Antivirals used in combination for the treatment of HIV infections
  9. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents. … Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.

  10. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.